CLDF Title
Contact Us | Bookmark
  HBV   HCC   HCV   HE   NASH   PBC   OTHER
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Featured Programs
      IC-Hep
 
             
  Liver News - REUTERS   Congress Calendar   Physician Resources  
 
 
Insurers increasingly deny coverage for all-oral hepatitis C regimens
06-15-2018
Sofosbuvir-velpatasvir-voxilaprevir effective in previously treated chronic hep C
06-12-2018
Israeli company Galmed gets positive trial results for liver drug
06-12-2018
Long-term HIV viral suppression tied to lower cancer risk
06-11-2018
Bezafibrate normalizes indicators of biliary cholangitis in some patients
06-06-2018
View Complete News Library
 
 
August 10-11
Advanced Hepatology Educational Summit for 3rd Year Fellows
Chicago, IL, USA
August 19-22
NCAD - National Conference on Addiction Disorders
Anaheim, CA, USA
September 7-9
GHAPP - Gastroenterology & Hepatology Advanced Practice Providers
Las Vegas, NV, USA
September 20-23
ALEH - Asociación Latinoamericana para el Estudio del Hígado (ALEH) / Latin American Association for the Study of the Liver
Punta Cana, Dominican Republic
October 3-7
IDSA - Infectious Diseases Society of America
San Francisco, CA, USA
View all Congresses
 
 
 
 
 
 
 
 
 
  Line  
  Featured Abstracts          
 
A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study
 
Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening
 
Improvement of Hepatic Fibrosis and Patient-Reported Outcomes in Non-Alcoholic Steatohepatitis Treated with Selonsertib
 
Treatment of hepatitis B: Is there still a role for interferon?
 
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B
 
 
8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
 
Prevalence and economic burden of extrahepatic manifestations of hepatitis Cvirus are underestimated but can be improved with therapy
 
Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations
 
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis Cinfection
 
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
 
 
Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy
 
Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014
 
 
          View All Abstracts  
  Line  
                               
 
HBV
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
 
HE
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
OTHER
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.